BRPI0407031A - Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 - Google Patents

Composições e métodos para tratamento de câncer empregando igsf9 e liv-1

Info

Publication number
BRPI0407031A
BRPI0407031A BR0407031-3A BRPI0407031A BRPI0407031A BR PI0407031 A BRPI0407031 A BR PI0407031A BR PI0407031 A BRPI0407031 A BR PI0407031A BR PI0407031 A BRPI0407031 A BR PI0407031A
Authority
BR
Brazil
Prior art keywords
polypeptides
igsf9
liv
methods
compositions
Prior art date
Application number
BR0407031-3A
Other languages
English (en)
Inventor
Karen Mclachlan
Scott Glaser
Robert J Peach
Tony Rowe
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of BRPI0407031A publication Critical patent/BRPI0407031A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA TRATAMENTO DE CâNCER EMPREGANDO IGSF9 E LIV-1". A presente invenção refere-se a polipeptídeos de IGSF9 e LIV-1 humanos e DNA (RNA) codificando tais polipeptídeos. Os polipeptídeos e/ou polinucleotídeo descritos são particularmente úteis na geração de anticorpos, ambos modificados e nativos, que ligam-se à IGSF9 ou LIV-1. São também descritas composições farmacêuticas e vacinas compreendendo os anticorpos, polipeptídeos e polinucleotídeos da invenção. São também descritos métodos para utilizar tais polipeptídeos para identificar ligandos, antagonistas e agonistas para os referidos polipeptídeos. Finalmente, métodos compreendendo as composições acima mencionadas são descritos para o tratamento, diagnose e/ou prognose de distúrbios neoplásicos.
BR0407031-3A 2003-01-27 2004-01-27 Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 BRPI0407031A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44253503P 2003-01-27 2003-01-27
PCT/US2004/002044 WO2004066933A2 (en) 2003-01-27 2004-01-27 Compositions and methods for treating cancer using igsf9 and liv-1

Publications (1)

Publication Number Publication Date
BRPI0407031A true BRPI0407031A (pt) 2006-01-17

Family

ID=32825236

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407031-3A BRPI0407031A (pt) 2003-01-27 2004-01-27 Composições e métodos para tratamento de câncer empregando igsf9 e liv-1

Country Status (16)

Country Link
US (2) US20040258616A1 (pt)
EP (1) EP1596806A4 (pt)
JP (1) JP2006520194A (pt)
KR (1) KR20050102627A (pt)
CN (1) CN1849337A (pt)
AU (1) AU2004207538A1 (pt)
BR (1) BRPI0407031A (pt)
CA (1) CA2514062A1 (pt)
EA (1) EA200501197A1 (pt)
IS (1) IS7960A (pt)
MX (1) MXPA05007940A (pt)
NO (1) NO20053986L (pt)
PL (1) PL379264A1 (pt)
RS (1) RS20050577A (pt)
WO (1) WO2004066933A2 (pt)
ZA (1) ZA200506671B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040141983A1 (en) * 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
WO2004067564A2 (en) 2003-01-29 2004-08-12 Protein Design Labs, Inc. Compositions against cancer antigen liv-1 and uses thereof
EP1709976A4 (en) * 2003-12-26 2007-10-17 Toshio Hirano EMT-INDUCING MEDIUM
US20090214517A1 (en) * 2004-07-27 2009-08-27 Justin Wong Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
TW200813231A (en) * 2006-04-13 2008-03-16 Novartis Vaccines & Diagnostic Methods of treating, diagnosing or detecting cancer
KR20110091423A (ko) * 2010-02-05 2011-08-11 국립암센터 항―ｔｍａｐ／ｃｋａｐ２ 항체를 포함하는 암의 예후 진단용 조성물
EP2648752B1 (en) 2010-12-06 2017-02-15 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer
MX2018010847A (es) 2016-03-15 2019-07-04 Seattle Genetics Inc Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico.
EP3555117B1 (en) 2017-05-09 2020-01-08 Cyano Biotech GmbH Modified microcystins
CN110563845A (zh) * 2019-09-12 2019-12-13 滨州医学院 抗igsf9抗体、药物组合物及其应用
KR20210122185A (ko) * 2020-03-31 2021-10-08 웰마커바이오 주식회사 Igsf1에 대한 항체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 및 이를 이용한 암 치료 방법
CN116082503B (zh) * 2022-08-19 2023-08-04 滨州医学院 一种靶向人igsf9的单克隆抗体及其应用
WO2024109944A1 (zh) * 2022-11-25 2024-05-30 江苏恒瑞医药股份有限公司 抗liv-1抗体、其药物偶联物及其医药用途
CN117379561B (zh) * 2023-10-13 2025-07-22 滨州医学院 一种靶向人igsf9的抗体偶联药物及其制备方法与应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) * 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) * 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5892019A (en) * 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
DE69120146T2 (de) * 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) * 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
DK0752248T3 (da) * 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
ATE236987T1 (de) * 1992-11-13 2003-04-15 Idec Pharma Corp Konsensus-kozak-sequenzen zur säugetier- exprimierung
CA2132500A1 (en) * 1994-09-20 1996-03-21 David Lockwood Manning Methods for predicting the behaviour of breast tumours
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
GB9524973D0 (en) * 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
MXPA02007190A (es) * 2000-01-25 2003-02-12 Genentech Inc Proteina relacionada a liv-1, polinucleotidos que codifican para la misma y uso de la misma para el tratamiento de cancer.
EP1346040A2 (en) * 2000-09-11 2003-09-24 Nuvelo, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
PL379264A1 (pl) 2006-08-07
ZA200506671B (en) 2006-09-27
CA2514062A1 (en) 2004-08-12
EP1596806A2 (en) 2005-11-23
JP2006520194A (ja) 2006-09-07
IS7960A (is) 2005-07-27
EA200501197A1 (ru) 2006-04-28
US20070071674A1 (en) 2007-03-29
NO20053986L (no) 2005-10-27
EP1596806A4 (en) 2007-08-29
CN1849337A (zh) 2006-10-18
KR20050102627A (ko) 2005-10-26
WO2004066933A2 (en) 2004-08-12
NO20053986D0 (no) 2005-08-26
RS20050577A (sr) 2007-09-21
US20040258616A1 (en) 2004-12-23
MXPA05007940A (es) 2007-06-14
WO2004066933A3 (en) 2006-03-02
AU2004207538A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
CY1118979T1 (el) Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
DE69933998D1 (de) Verbindungen und verfahren für therapie und diagnose von lungenkrebs
BRPI0513681A (pt) composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer
AR038568A1 (es) Anticuerpos anti-a beta y su uso
BR0213303A (pt) Proteìnas de ligação de alvejamento direto
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
CY1110923T1 (el) Συζυγη που περιλαμβανουν ενα αντισωμα ειδικο για την ed-β περιοχη της ινονεκτινης και η χρηση τους για τον εντοπισμο και την αντιμετωπιση ογκων
BRPI0418766A (pt) anticorpos e moléculas derivadas destes que se ligam às proteìnas steap-1
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
CO4600637A1 (es) Compuestos para inmunoterapia e inmunodiagnosis del cancer de prostata
DE60224291D1 (de) System zur antikörperexpression und- synthese
ATE454447T1 (de) Peptidagonisten für prostata-spezifisches antigen und ihre verwendung
BRPI0808940A8 (pt) anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
FI20011664A7 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
FI20011671A7 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
MA28041A1 (fr) Molecules de liaison therapeutiques
BR0210905A (pt) Anticorpos especìficos para cd44v6
BRPI0409736A (pt) anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados
WO2003105773A3 (en) Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets:

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.